Exagen Statistics
Total Valuation
Exagen has a market cap or net worth of $23.79 million. The enterprise value is $10.52 million.
| Market Cap | 23.79M |
| Enterprise Value | 10.52M |
Important Dates
The next estimated earnings date is Monday, May 13, 2024, after market close.
| Earnings Date | May 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Exagen has 17.24 million shares outstanding. The number of shares has increased by 3.50% in one year.
| Shares Outstanding | 17.24M |
| Shares Change (YoY) | +3.50% |
| Shares Change (QoQ) | +0.82% |
| Owned by Insiders (%) | 30.42% |
| Owned by Institutions (%) | 59.29% |
| Float | 7.10M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.45 |
| Forward PS | 0.43 |
| PB Ratio | 1.05 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.20 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.02, with a Debt / Equity ratio of 1.02.
| Current Ratio | 4.02 |
| Quick Ratio | 3.62 |
| Debt / Equity | 1.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -9.13 |
Financial Efficiency
Return on equity (ROE) is -80.30% and return on invested capital (ROIC) is -49.73%.
| Return on Equity (ROE) | -80.30% |
| Return on Assets (ROA) | -36.30% |
| Return on Capital (ROIC) | -49.73% |
| Revenue Per Employee | $302,000 |
| Profits Per Employee | -$136,144 |
| Employee Count | 174 |
| Asset Turnover | 0.80 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Exagen has paid $33,000 in taxes.
| Income Tax | 33,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -44.80% in the last 52 weeks. The beta is 1.19, so Exagen's price volatility has been higher than the market average.
| Beta (1Y) | 1.19 |
| 52-Week Price Change | -44.80% |
| 50-Day Moving Average | 1.72 |
| 200-Day Moving Average | 2.00 |
| Relative Strength Index (RSI) | 36.37 |
| Average Volume (30 Days) | 38,977 |
Short Selling Information
The latest short interest is 20,475, so 0.12% of the outstanding shares have been sold short.
| Short Interest | 20,475 |
| Short Previous Month | 5,167 |
| Short % of Shares Out | 0.12% |
| Short % of Float | 0.29% |
| Short Ratio (days to cover) | 0.35 |
Income Statement
In the last 12 months, Exagen had revenue of $52.55 million and -$23.69 million in losses. Loss per share was -$1.34.
| Revenue | 52.55M |
| Gross Profit | 29.46M |
| Operating Income | -22.84M |
| Pretax Income | -23.66M |
| Net Income | -23.69M |
| EBITDA | -18.21M |
| EBIT | -21.32M |
| Loss Per Share | -$1.34 |
Balance Sheet
The company has $36.49 million in cash and $23.23 million in debt, giving a net cash position of $13.26 million or $0.77 per share.
| Cash & Cash Equivalents | 36.49M |
| Total Debt | 23.23M |
| Net Cash | 13.26M |
| Net Cash Per Share | $0.77 |
| Equity / Book Value | 22.69M |
| Book Value Per Share | 1.32 |
| Working Capital | 35.94M |
Cash Flow
In the last 12 months, operating cash flow was -$14.46 million and capital expenditures -$804,000, giving a free cash flow of -$15.27 million.
| Operating Cash Flow | -14.46M |
| Capital Expenditures | -804,000 |
| Free Cash Flow | -15.27M |
| FCF Per Share | -$0.86 |
Margins
Gross margin is 56.06%, with operating and profit margins of -43.46% and -45.08%.
| Gross Margin | 56.06% |
| Operating Margin | -43.46% |
| Pretax Margin | -45.02% |
| Profit Margin | -45.08% |
| EBITDA Margin | -34.66% |
| EBIT Margin | -40.57% |
| FCF Margin | -29.05% |
Dividends & Yields
Exagen does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.50% |
| Shareholder Yield | -3.50% |
| Earnings Yield | -99.60% |
| FCF Yield | -64.18% |
Analyst Forecast
The average price target for Exagen is $6.00, which is 334.78% higher than the current price. The consensus rating is "Buy".
| Price Target | $6.00 |
| Price Target Difference | 334.78% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | 15.80% |
| EPS Growth Forecast (5Y) | -17.08% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Exagen has an Altman Z-Score of -6 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6 |
| Piotroski F-Score | 4 |